Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PepGen Inc. (PEPG)

PepGen narrows Q1 net loss to $17.8M; FDA places partial clinical hold on trial

Mixed Impact 3 of 5 earnings Written later

PepGen reported a first quarter 2026 net loss of $17.8 million, or $(0.26) per share, down from $30.2 million, or $(0.92) per share, a year earlier, as research and development expenses fell to $13.0 million from $25.4 million. The company also disclosed that the FDA placed a partial clinical hold on its FREEDOM2 study of PGN-EDODM1, which PepGen says relates to previously submitted preclinical studies and has not affected the ongoing trial's timing, and that cash and marketable securities were $132.3 million as of March 31, 2026.

Key points

  • Q1 2026 net loss was $17.8 million, or $(0.26) per share, versus $30.2 million, or $(0.92) per share, in Q1 2025.
  • Research and development expenses were $13.0 million, compared with $25.4 million a year earlier; general and administrative expenses were $5.9 million in both periods.
  • The FDA placed a partial clinical hold on the FREEDOM2 study, tied to questions about previously submitted preclinical pharmacology and toxicology studies.
  • Cash, cash equivalents and marketable securities were $132.3 million at March 31, 2026, down from $148.5 million at December 31, 2025, and PepGen expects this to fund operations into the second half of 2027.

The filing

CompanyPepGen Inc. (PEPG)
Form8-K, current report
Filed with the SECMay 12, 2026, 4:10 PM ET
Accession number0001193125-26-219424

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.